suramin has been researched along with Breast Neoplasms in 28 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin inhibits the growth of non-small cell lung cancer (NSCLC) and breast cancer in vitro by blocking the action of most known growth factors." | 9.08 | Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. ( Bergh, J; Jakobsen, E; Lindebjerg-Clasen, B; Mirza, MR; Pfeiffer, P; Rose, C, 1997) |
| "The anti-proliferative effects of suramin were investigated in two oestrogen dependent breast cancer lines (ZR-75-1 and MCF-7), oestrogen independent (ZR-PR-LT) and tamoxifen resistant (ZR-75-9a1) variants of ZR-75-1 and a tamoxifen resistant (LY2) variant of MCF-7." | 7.70 | The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of ta ( Boylan, M; Lynch, M; van den Berg, HW, 1998) |
| "The antiestrogen tamoxifen is commonly used to treat breast cancer, but it also has therapeutic activity in several other types of cancer." | 7.70 | Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. ( Couldwell, WT; Lin, JH; Nedergaard, M; Song, H; Takano, T; Zhang, W, 2000) |
| "The polyanionic compound suramin can inhibit the proliferation of cells of various origin, including from breast cancer." | 7.68 | Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro. ( Foekens, JA; Klijn, JG; Peters, HA; Sieuwerts, AM; Stuurman-Smeets, EM, 1993) |
| "In this study, the polyanionic compound suramin was shown to be a potent in vitro growth inhibitor of both hormone-insensitive, estrogen receptor-negative human breast cancer cells (MDA MB231 and SK-BR-3) and hormone-responsive, estrogen receptor-positive human breast cancer cells (ZR 75-1, T47D, and MCF7)." | 7.68 | Inhibition of breast cancer growth by suramin. ( Prebois, C; Rochefort, H; Vignon, F, 1992) |
| " We hypothesized that suramin at non-cytotoxic doses in combination with weekly paclitaxel would be well tolerated and demonstrate anti-tumor activity." | 6.77 | Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ( Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012) |
| "Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis." | 6.69 | A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. ( Benson, AB; Bouck, N; Cisneros, A; French, S; Gradishar, WJ; Liu, J; Rademaker, A; Soff, G, 2000) |
| "The treatment of patients with invasive breast cancer remains a major issue because of the acquisition of drug resistance to conventional chemotherapy." | 5.40 | A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells. ( Borges, S; Döppler, HR; Storz, P, 2014) |
| "Suramin inhibits the growth of non-small cell lung cancer (NSCLC) and breast cancer in vitro by blocking the action of most known growth factors." | 5.08 | Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. ( Bergh, J; Jakobsen, E; Lindebjerg-Clasen, B; Mirza, MR; Pfeiffer, P; Rose, C, 1997) |
| "Suramin has shown promising activity against prostate and breast cancer but is severely neurotoxic." | 5.07 | Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. ( George, N; Howell, A; Margison, J; Ranson, M; Thomson, Y; van der Water, L; Woll, PJ, 1994) |
| "The anti-proliferative effects of suramin were investigated in two oestrogen dependent breast cancer lines (ZR-75-1 and MCF-7), oestrogen independent (ZR-PR-LT) and tamoxifen resistant (ZR-75-9a1) variants of ZR-75-1 and a tamoxifen resistant (LY2) variant of MCF-7." | 3.70 | The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of ta ( Boylan, M; Lynch, M; van den Berg, HW, 1998) |
| "The antiestrogen tamoxifen is commonly used to treat breast cancer, but it also has therapeutic activity in several other types of cancer." | 3.70 | Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. ( Couldwell, WT; Lin, JH; Nedergaard, M; Song, H; Takano, T; Zhang, W, 2000) |
| "The polyanionic compound suramin can inhibit the proliferation of cells of various origin, including from breast cancer." | 3.68 | Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro. ( Foekens, JA; Klijn, JG; Peters, HA; Sieuwerts, AM; Stuurman-Smeets, EM, 1993) |
| "In this study, the polyanionic compound suramin was shown to be a potent in vitro growth inhibitor of both hormone-insensitive, estrogen receptor-negative human breast cancer cells (MDA MB231 and SK-BR-3) and hormone-responsive, estrogen receptor-positive human breast cancer cells (ZR 75-1, T47D, and MCF7)." | 3.68 | Inhibition of breast cancer growth by suramin. ( Prebois, C; Rochefort, H; Vignon, F, 1992) |
| " We hypothesized that suramin at non-cytotoxic doses in combination with weekly paclitaxel would be well tolerated and demonstrate anti-tumor activity." | 2.77 | Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ( Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG, 2012) |
| "Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis." | 2.69 | A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. ( Benson, AB; Bouck, N; Cisneros, A; French, S; Gradishar, WJ; Liu, J; Rademaker, A; Soff, G, 2000) |
| "The treatment of patients with invasive breast cancer remains a major issue because of the acquisition of drug resistance to conventional chemotherapy." | 1.40 | A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells. ( Borges, S; Döppler, HR; Storz, P, 2014) |
| "Suramin is an experimental antineoplastic agent which is currently being tested in clinical trials for its utility in treating breast and prostate cancer." | 1.30 | Role of ceramide in suramin-induced cancer cell death. ( Gill, JS; Windebank, AJ, 1997) |
| "Suramin has shown antitumour activity in vitro and in vivo." | 1.29 | The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994) |
| "Cell lines used were as follows: cervical cancer (HeLa), mammary cancer (MCF-7), bladder cancer (EJ), hepatoma (HuH-7, PLC/PRF/5), embryonal carcinoma (PA-1), and three in vitro transformed human fibroblast lines (KMST-6, SUSM-1, and VA-13)." | 1.28 | [Effects of suramin on cell proliferation of various types of human malignant cells]. ( Bai, LY; Miyazaki, M; Namba, M, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (64.29) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 4 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borges, S | 1 |
| Döppler, HR | 1 |
| Storz, P | 1 |
| Singla, AK | 1 |
| Bondareva, A | 1 |
| Jirik, FR | 1 |
| Koval, A | 1 |
| Ahmed, K | 1 |
| Katanaev, VL | 1 |
| Kawai, Y | 1 |
| Kaidoh, M | 1 |
| Ohhashi, T | 1 |
| Lustberg, MB | 1 |
| Pant, S | 1 |
| Ruppert, AS | 1 |
| Shen, T | 1 |
| Wei, Y | 2 |
| Chen, L | 1 |
| Brenner, L | 1 |
| Shiels, D | 1 |
| Jensen, RR | 1 |
| Berger, M | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Grever, M | 1 |
| Au, JL | 2 |
| Wientjes, MG | 2 |
| Shapiro, CL | 1 |
| Song, S | 1 |
| Yu, B | 1 |
| Gow, IF | 2 |
| Thomson, J | 2 |
| Davidson, J | 1 |
| Shennan, DB | 2 |
| Garrido, T | 1 |
| Riese, HH | 1 |
| Aracil, M | 1 |
| Pérez-Aranda, A | 1 |
| Lopez Lopez, R | 1 |
| van Rijswijk, RE | 1 |
| Wagstaff, J | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Woll, PJ | 1 |
| Ranson, M | 1 |
| Margison, J | 1 |
| Thomson, Y | 1 |
| van der Water, L | 1 |
| George, N | 1 |
| Howell, A | 1 |
| Ravera, F | 1 |
| Miglietta, L | 1 |
| Pirani, P | 1 |
| Ferrini, S | 1 |
| Favoni, RE | 1 |
| Foekens, JA | 2 |
| Sieuwerts, AM | 2 |
| Stuurman-Smeets, EM | 2 |
| Peters, HA | 1 |
| Klijn, JG | 2 |
| Cheson, BD | 1 |
| Phillips, PH | 1 |
| Pluda, JM | 1 |
| Christian, M | 1 |
| Harris, AL | 1 |
| Zhang, H | 1 |
| Moghaddam, A | 1 |
| Fox, S | 1 |
| Scott, P | 1 |
| Pattison, A | 1 |
| Gatter, K | 1 |
| Stratford, I | 1 |
| Bicknell, R | 1 |
| Mirza, MR | 1 |
| Jakobsen, E | 1 |
| Pfeiffer, P | 1 |
| Lindebjerg-Clasen, B | 1 |
| Bergh, J | 1 |
| Rose, C | 1 |
| Boylan, M | 1 |
| van den Berg, HW | 1 |
| Lynch, M | 1 |
| Gill, JS | 1 |
| Windebank, AJ | 1 |
| Lawrence, JB | 1 |
| Conover, CA | 1 |
| Haddad, TC | 1 |
| Ingle, JN | 1 |
| Reid, JM | 1 |
| Ames, MM | 1 |
| Suman, VJ | 1 |
| Marks, RS | 1 |
| Erlichman, C | 1 |
| Hartmann, LC | 1 |
| Gradishar, WJ | 1 |
| Soff, G | 1 |
| Liu, J | 1 |
| Cisneros, A | 1 |
| French, S | 1 |
| Rademaker, A | 1 |
| Benson, AB | 1 |
| Bouck, N | 1 |
| Zhang, W | 1 |
| Couldwell, WT | 1 |
| Song, H | 1 |
| Takano, T | 1 |
| Lin, JH | 1 |
| Nedergaard, M | 1 |
| Weckbecker, G | 1 |
| Liu, R | 1 |
| Tolcsvai, L | 1 |
| Berthois, Y | 1 |
| Dong, XF | 1 |
| Martin, PM | 1 |
| Cvitkovic, E | 1 |
| Dorssers, LC | 1 |
| Berns, EM | 1 |
| Wellstein, A | 1 |
| Zugmaier, G | 1 |
| Califano, JA | 1 |
| Kern, F | 1 |
| Paik, S | 1 |
| Lippman, ME | 1 |
| Eisenberger, MA | 1 |
| Fontana, JA | 1 |
| Vignon, F | 1 |
| Prebois, C | 1 |
| Rochefort, H | 1 |
| Bai, LY | 1 |
| Miyazaki, M | 1 |
| Namba, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer.[NCT01608451] | Phase 3 | 800 participants (Actual) | Interventional | 2007-09-30 | Terminated (stopped due to Slow accrual implies that clinical questions being questioned have lost its significance.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for suramin and Breast Neoplasms
| Article | Year |
|---|---|
Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting.
Topics: Angiogenesis Inducing Agents; Breast Neoplasms; Female; Genetic Therapy; Humans; Neovascularization, | 1996 |
5 trials available for suramin and Breast Neoplasms
| Article | Year |
|---|---|
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2012 |
Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Topics: Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; F | 1994 |
Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans | 1997 |
Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Hydrocortis | 1997 |
A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female | 2000 |
22 other studies available for suramin and Breast Neoplasms
| Article | Year |
|---|---|
A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cell Line, T | 2014 |
Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Lin | 2014 |
Inhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosis.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Endocytosis; Female; HEK293 Ce | 2016 |
MDA-MB-231 produces ATP-mediated ICAM-1-dependent facilitation of the attachment of carcinoma cells to human lymphatic endothelial cells.
Topics: Adenosine Triphosphate; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Culture Media, Conditione | 2008 |
Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2004 |
The effect of a hyposmotic shock and purinergic agonists on K+(Rb+) efflux from cultured human breast cancer cells.
Topics: Adenosine Triphosphate; Apamin; Breast Neoplasms; Calcium; Cell Line, Tumor; Charybdotoxin; Dose-Res | 2005 |
Osmoregulation of taurine efflux from cultured human breast cancer cells: comparison with volume activated Cl- efflux and regulation by extracellular ATP.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Adenosine; Adenosine Triphosphate; Biological Tran | 2006 |
Endothelial cell differentiation into capillary-like structures in response to tumour cell conditioned medium: a modified chemotaxis chamber assay.
Topics: Adenocarcinoma; Animals; Antibodies; Aorta; Breast Neoplasms; Capillaries; Cattle; Cell Differentiat | 1995 |
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi | 1994 |
Suramin-induced growth inhibition and insulin-like growth factor-I binding blockade in human breast carcinoma cell lines: potentially related events.
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Insuli | 1993 |
Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; Estradiol; Female; Humans; Insul | 1993 |
Clinical trials referral resource. Clinical trials of suramin.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Humans; Leukemia; Lymphoma; Suram | 1995 |
The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of ta
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Resis | 1998 |
Role of ceramide in suramin-induced cancer cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Ceramides; DNA Fragmenta | 1997 |
Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells.
Topics: Adenosine Triphosphate; Adult; Animals; Antineoplastic Agents, Hormonal; Astrocytes; Breast Neoplasm | 2000 |
Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line; Female; Fibroblast G | 1992 |
Antagonism by suramin of the growth-inhibitory effect of hydroxytamoxifen and doxorubicin in human MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Doxorubicin; Drug Interactions; Drug Resistance; Humans; Suramin; T | 1992 |
Pleiotropic actions of suramin on the proliferation of human breast-cancer cells in vitro.
Topics: Breast Neoplasms; Cell Division; Culture Media, Serum-Free; Drug Screening Assays, Antitumor; Hemato | 1992 |
Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate.
Topics: Adrenal Gland Neoplasms; Animals; Breast Neoplasms; Cell Division; Endothelium, Vascular; Female; Fi | 1991 |
Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Clinical Trials as Topic; Female; Humans; Ma | 1992 |
Inhibition of breast cancer growth by suramin.
Topics: Breast Neoplasms; Cathepsin D; Cell Division; Dose-Response Relationship, Drug; Epidermal Growth Fac | 1992 |
[Effects of suramin on cell proliferation of various types of human malignant cells].
Topics: Breast Neoplasms; Carcinoma, Hepatocellular; Cell Division; Female; Humans; Liver Neoplasms; Male; S | 1991 |